Department of Gastroenterology, Hospital Universitario de Fuenlabrada, Camino del Molino 2, Madrid 28942, Spain.
Expert Rev Gastroenterol Hepatol. 2013 Jan;7(1):41-8. doi: 10.1586/egh.12.64.
Anti-TNF agents are widely used in the treatment of some inflammatory diseases, such as inflammatory bowel disease and psoriasis. Their use has led to a significant advance in the treatment of these diseases. Paradoxically, the onset of psoriatic lesions has been observed in patients on anti-TNF treatment. The cause of this side effect has not yet been clearly identified. In recent years, an increasing number of cases of psoriasis related to anti-TNF therapy in inflammatory bowel disease patients have been reported. Although withdrawal of anti-TNF was usually implemented in the first reports, in more recent series the maintenance of the drug with topical therapy, with the exception of the most severe or extensive forms of skin lesions, appears to be the treatment of choice. This article summarizes the relevant literature, discusses the etiopathology, epidemiology, location and phenotypes of psoriatic lesions and the management of this side effect.
抗 TNF 制剂广泛用于治疗某些炎症性疾病，如炎症性肠病和银屑病。它们的使用在这些疾病的治疗上取得了显著的进步。矛盾的是，在接受抗 TNF 治疗的患者中观察到了银屑病病变的发作。这种副作用的原因尚未明确。近年来，越来越多的炎症性肠病患者在接受抗 TNF 治疗时出现银屑病的病例报告。虽然在最初的报告中通常会停用抗 TNF，但在最近的一系列报告中，对于皮肤病变最严重或最广泛的患者，除了药物外，还需要进行局部治疗，这似乎是治疗的首选方法。本文总结了相关文献，讨论了银屑病病变的发病机制、流行病学、位置和表型，以及这种副作用的管理。
